The mortality rate after transthoracic echocardiography with a perflutren-based ultrasound contrast agent was 28% lower than with noncontrast echocardiography at 48 hours in critically ill patients in a study reported in the journal Cardiovascular Imaging. "These results are reassuring, given previous reports suggesting an association between ultrasound contrast agents and increased mortality in critically ill patients," wrote researchers.

Related Summaries